Watching GBS; Zacks Small-Cap Research Sets $4.50 Valuation
$GBS
Industrial Machinery/Components
Industrials
Watching GBS; Zacks Small-Cap Research Sets $4.50 Valuation
Save time and jump to the most important pieces.
SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 9.09% to $0.84. The market value of their outstanding shares is at $36.1 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 9.06% to $0.11. The company's market cap stands at $8.7 million. Aytu BioPharma (NASDAQ:AYTU) shares increased by 8.38% to $0.22. The market value of their outstanding shares is at $13.7 million. BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.74% to $0.33. The market value of their outstanding shares is at $12.4 million. Losers Eiger BioPharmaceuticals (NASD
The transaction further solidifies GBS' leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reach GBS' global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name.
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
The transaction further solidifies GBS' leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS' global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name. I
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financi
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call & WebcastDate:Wednesday, August 31, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 1
The transaction further solidifies GBS' leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS' global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name. I
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financi
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call & WebcastDate:Wednesday, August 31, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 1